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ABSTRACT 
The transcription factor STAT3 acts downstream of many pro-oncogenic signals, including 
cytokines, growth factors and oncogenes, and is accordingly constitutively activein a wide variety 
of tumors that often become addicted to it. Moreover, STAT3 is a key player in mediating 
inflammation-driven tumorigenesis, where its aberrant continuous activation is typically triggered 
by local or systemic production of the pro-inflammatory cytokine IL-6. We recently showed that 
MEFs derived from STAT3C k/in mice, which express physiological levels of the constitutively 
active mutant STAT3C, display features of transformed cells such as increased proliferation, 
resistance to apoptosis and senescence, and aerobic glycolysis. Here, we show that pre-existing 
constitutively active STAT3 is sufficient to prime primary MEFs for malignant transformation upon 
spontaneous immortalization. Transformation is strictly STAT3-dependent and correlates with high 
resistance to apoptosis and enhanced expression of anti-apoptotic/pro-survival genes. Additionally, 
HIF-1α level is elevated by 2-fold and contributes to STAT3oncogenic activity by supporting high 
rates of aerobic glycolysis. Thus, constitutively active STAT3, an accepted essential factor for 
tumor growth/progression, can also act as a first hit in multistep carcinogenesis; this ability to 
predispose cells to malignant transformation may be particularly relevant in the pro-oncogenic 
niche represented by chronically inflamed tissues. 
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INTRODUCTION 
 Signal Transducers and Activators of Transcription (STAT) factors mediate the signalling 
downstream of cytokine and growth factor receptors1,2. Once activated by tyrosine-phosphorylation 
via receptor-associated JAK kinases, STATs concentrate into the nucleus and regulate the 
expression of target genes3. STAT3 can be activated by a wide variety of cytokines and growth 
factors and by a number of oncogenes4, and is accordingly constitutively phosphorylated on 
tyrosine in many tumors that often become addicted to its activity4-7. Indeed, STAT3 is required for 
cell transformation downstream of v-Src and many other oncogenes5,8,9, and overexpression of a 
constitutively active mutant form can transform immortalized fibroblasts and epithelial cells10,11. 
Even though STAT3 is often referred to as an oncogene, no naturally occurring activating mutations 
are know, and its aberrant activity in tumors mostly occurs downstream of multiple activated pro-
oncogenic pathways. Importantly, STAT3 is a key player in mediating inflammation-driven 
tumorigenesis, being constitutively activated by chronically high levels of the pro-inflammatory 
cytokine IL-612. In tumors, STAT3 is known to enhance cell survival and proliferation and to 
promote immune escape and angiogenesis, invasion and metastasis13,14.  
 In an effort to characterize pro-oncogenic functions of continuous, weak STAT3 activation, 
we have recently generated knock-in mice expressing physiological levels of the constitutively 
active STAT3C mutant form15. We have shown that constitutively active STAT3 acts as a master 
regulator of cell metabolism, promoting aerobic glycolysis and down-regulating mitochondrial 
activity via its canonical, nuclear functions both in STAT3C/C MEFs and in STAT3-addicted 
tumoral cells16. On the other hand, mitochondrially localized STAT3 was recently demonstrated to 
play a role in preserving mitochondrial respiratory activity via its serine-phosphorylated form17,18. 
Both activities contribute to malignant transformation downstream of distinct signals, which 
promote STAT3 phosphorylation on either tyrosine or serine thus activating nuclear or 
mitochondrial STAT3 (nSTAT3, mSTAT3) (Demaria et al., Cell Cycle, in press). While aerobic 
glycolysis induced by nuclear STAT3 is dependent on the transcriptional induction of the oxygen-
sensor HIF-1α, down-regulation of mitochondrial function is HIF-1α-independent16. HIF-1 is 
composed of a constitutively expressed β subunit and an O2-regulated α subunit19, HIF-1α, which 
undergoes O2-dependent hydroxylation leading to its proteasomal degradation20. Under hypoxic 
conditions, hydroxylation is inhibited and HIF-1α rapidly accumulates and dimerizes with HIF-1β, 
becoming transcriptionally active. Oncogenic pathways can lead to HIF-1α accumulation even 
under normoxia19, and its enhancedactivity correlates with poor prognosis in human cancer such as 
those of the breast, prostate and melanomas21-23.  HIF-1α target genes control both oxygen delivery 
and usage via induction of angiogenesis and glycolysis, respectively, and this factor is one of the 
key players in inducing the Warburg effect, i.e. the ability of most cancer cells to undergo aerobic 
glycolysis24,25.  
 Mouse embryonic cells (MEFs) can be spontaneously immortalized via regular passages 
during which, after undergoing a proliferative senescence crisis, a few immortalized cells emerge  
(the 3T3 protocol26). 3T3-immortalized MEFs are not tumorigenic but, in contrast to their primary 
counterparts, can undergo full transformation when challenged with a single oncogene27. Primary 
MEFs derived from STAT3C mice (Stat3C/C MEFs) are not spontaneously transformed but show 
pre-oncogenic properties, such as increased proliferation, resistance to apoptosis and senescence 
and increased aerobic glycolysis with enhanced glucose dependence16. Here we show that 
spontaneous immortalization via the 3T3 protocol leads to complete transformation, demonstrating 
that continuous STAT3 activity can act as a first hit in tumorigenesis. This has important 
implications for understanding the mechanisms leading to inflammation-driven cancer, where 
chronically active STAT3 precedes tumor transformation. 
 
 
 
 
 
RESULTS 
Immortalization triggers tumorigenic transformation in Stat3C/C MEFs. MEFs derived from 2 
individual Stat3C/C or Stat3WT/WT embryos were subjected to the 3T3 spontaneous immortalization 
protocol26. Compared to wild type cells, Stat3C/C MEFs underwent a delayed and much shorter 
proliferative crisis, which peaked at passage (P) 16 as compared to P10 of their wild type 
counterparts (Figure 1a). Cells never completely ceased duplicating and a rapidly proliferating 
population arose earlier than in Stat3WT/WT MEFs (P20 versus P24). Immortalized cell lines were 
completely established after 26 passages for both genotypes (two independent experiments). Similar 
to what we observed in the primary cells, 3T3-immortalized Stat3C/C MEFs displayed increased 
expression of the STAT3 canonical target gene Socs3, confirming higher STAT3 transcriptional 
activity, and proliferated much faster than their wild type counterparts (Figure 1b, c). However, in 
contrast to primary Stat3C/C MEFs, both of the immortal Stat3C/C cell lines (C1 and C2) acquired the 
ability to grow in multi-layers, a feature typical of transformed cells (Figure 2a). Further, both C1 
and C2 were able to give rise to foci in a classical focus forming assay (FFA), while immortal 
Stat3WT/WT cells were never able to do so (Figure 2b). Immortal Stat3C/C cells were also capable of 
anchorage-independent growth, giving rise to colonies in soft agar (Figure 2c). The ultimate test for 
in vitro tumor transformation is considered the ability to grow in vivo in immune-compromised 
mice. 106 immortal Stat3C/C or Stat3WT/WT MEFs were inoculated subcutaneously (s.c.) into nude 
mice. After 10-12 days the Stat3C/C cells gave rise to palpable tumors, which reached 1 cm diameter 
by six weeks, time of sacrifice (Figure 2e). As expected, Stat3WT/WT cells were never able to give 
rise to tumors.  
 Thus, immortal Stat3C/C cells display the hallmark of fully malignant tumor cells, suggesting 
that constitutively active STAT3 can indeed act as a first hit in tumorigenesis. Interestingly, the 
transformed phenotype remained completely dependent on STAT3 activity, as shown by the 
observation that Stat3 silencing completely abolished in vivo growth (Figure 2d, e). 
 
Resistance to apoptosis of the immortal Stat3C/C MEFs. 
STAT3 has been linked to apoptosis resistance in many tumors and experimental systems, including 
cells over-expressing STAT3C10. In order to assess the ability of the transformed Stat3C/C cells to 
survive apoptotic stimuli, immortal Stat3C/C and Stat3WT/WT  cells were exposed to UV-B light (10 
J/m2), followed by apoptotic index assessment using a cytofluorimeter and Annexin V staining. 
Indeed, and similar to the primary cells of the same genotype, immortal Stat3C/C cells were 
significantly protected from apoptotic cell death compared to their wild type counterparts (Figure 
3a). In order to evaluate activation of the pro-apoptotic caspase cascade, the levels of active 
caspase-3 were measured by either immunofluorescence or western blotting after UV irradiation 
(Figure 3b and Supplementary Figure 1a). Caspase-3 activation was lower in Stat3C/C cells, 
confirming a general down-regulation of the apoptotic cascade. Immortal Stat3C/C cells were also 
protected from starvation-induced apoptosis (Supplementary Figure 1b), in agreement with the idea 
that STAT3 acts as an anti-apoptotic factor in response to different pro-apoptotic stimuli. 
 Since STAT3 was proposed to directly regulate a number of anti-apoptotic genes, we 
assessed a panel of pro- and anti-apoptotic mRNAs by qRT-PCR (not shown). Immortal Stat3C/C 
cells expressed higher levels of the anti-apoptotic genes bcl-2, bcl2-l1 and bcl-3, all known STAT3 
targets, which could well mediate the observed resistance to apoptosis (Figure 3c). Moreover, the 
levels of the inhibitor of apoptosis (IAP) gene family member birc-5, also known as survivin, were 
induced by 4-fold upon UV irradiation in the Stat3C/C cells but not in the wild-type cells (Figure 3d). 
Birc-5/survivin was also previously shown to be a direct STAT3 transcriptional target, and its 
increased level may help in maintaining the caspase cascade activation at a low level.   
Immortal Stat3C/C MEFs display STAT3-dependent aerobic glycolysis. 
We recently showed that constitutively active STAT3 promotes aerobic glycolysis in both primary 
Stat3C/C MEFs and in STAT3-dependent human tumor cell lines via the transcriptional up-
regulation of Hif-1α16. To assess glucose metabolism in the immortalized cell lines, a number of 
glycolysis parameters were evaluated. Similar to the primary cells, immortal Stat3C/C MEFs 
displayed increased levels of Hif-1α and of several of its target genes known to be involved in 
glycolysis such as pyruvate dehydrogenase kinase (Pdk-1), lactate dehydrogenase (Ldh-a) and 
phospho-fructokinase-1 (Pfk-l) (Figure 4a). Accordingly, immortal Stat3C/C MEFs produced higher 
lactate levels, thus confirming enhanced aerobic glycolysis (Figure 4b). Both lactate production and 
the Hif-1α level were dependent on STAT3 activity, as they were normalized by STAT3 silencing. 
(Figure 4c, d).  
Hif-1α silencing impairs aerobic glycolysis but only partially reverts the transformed 
phenotype of immortalized Stat3C/C MEFs. 
Hif-1α is often up-regulated in cancer, particularly in late-stage tumors, where it helps protect cells 
from hypoxia by activating glycolysis and stimulating angiogenesis. Hif-1α silencing down-
regulated aerobic glycolysis in primary Stat3C/C MEFs, relieving their glucose dependence. 
Interfering with Hif-1α expression dramatically reduced the transcription of glycolysis-related 
genes and the production of lactate, confirming that indeed STAT3-dependent aerobic glycolysis is 
mediated by Hif-1α also in the immortal Stat3C/C MEFs (Figure 5a, b). In contrast to what observed 
in the primary cells, however, Hif-1α silencing also restored mitochondrial activity, as measured by 
mitochondrial-Ca2+ uptake, to levels similar to those of the wild type cells (Figure 5c). Additionally, 
silencing of Hif-1α reduced the proliferation rates of immortal Stat3C/C cells (not shown), but only 
partially reversed other transformed phenotypes. Thus, the ability of immortal Hif-1α-silenced 
Stat3C/C MEFs to form foci and soft agar colonies, as well as their in vivo growth rates,were 
significantly reduced but not abolished (Figures 4d,e). These data suggest that the oncogenic 
properties of a constitutively active STAT3 partly rely on Hif-1α up-regulation and the consequent 
metabolic switch towards aerobic glycolysis. 
 
DISCUSSION 
 Constitutive, oncogenic STAT3 activity is believed to stem from the aberrant activation of 
many oncogenic pathways, which ultimately induce its tyrosine phosphorylation1. The pro-
oncogenic role of STAT3 was shown for the first time by the finding that overexpression of the 
constitutively active mutant form, STAT3C, can transform cultured cells10,11,28. Further, in vivo, 
overexpression of STAT3C was shown to enhance malignant progression of skin tumors29 and 
trigger the onset of lung adenocarcinomas30. However, STAT3 activation in tumors most often does 
not entail increased protein levels, in keeping with the idea that oncogenic STAT3 activation is the 
leading mechanism31 and suggesting that overexpression is probably not the best experimental 
system to assess the mechanisms of STAT3-mediated tumorigenesis.  
 We recently showed that expression of STAT3C at physiological levels can cooperate with 
the Neu oncogene to drive invasive breast cancer15, and that STAT3C knock-in MEFs display 
features of transformed cells such as increased proliferation, resistance to apoptosis and senescence, 
and aerobic glycolysis16. Here, we show for the first time that pre-existing physiological levels of 
constitutively active STAT3 are sufficient to transform primary cells to full malignancy following 
immortalization in a 3T3 protocol, suggesting that low and chronic activity of STAT3 may suffice 
as a first hit in multistep carcinogenesis. This finding is of particular relevance for the emerging key 
role of STAT3 in inflammation-driven cancer. It has been shown that chronic inflammation, 
entailing a positive loop between the transcription factor NF-kB, the pro-inflammatory cytokine IL-
6 and the IL-6-activated STAT3, is a highly predisposing condition for cancer, particularly in the 
colon, the liver and the breast32. In addition, to generate a favorable niche for the growth of tumor 
cells via the production of pro-oncogenic signals, our data show now that cells exposed to chronic 
IL-6 signaling, displaying continuous STAT3 activation, can behave like cells that have undergone 
a first oncogenic mutation. These cells will therefore be exquisitely sensitive to further mutagenic 
events, which are favored by the inflammatory microenvironment that contains cytokines, growth 
factors and reactive oxygen species. 
 The mechanism through which constitutively active STAT3 sensitizes cells to tumorigenic 
transformation is probably many-fold and observed in either our Stat3C/C primary16 or immortalized 
MEFs: first, protection from apoptosis; second, delayed senescence; third, increased proliferation; 
fourth, increased glycolytic metabolism. Protection from apoptosis, induced by different stress 
stimuli, correlates with the increased expression of anti-apoptotic genes. Delayed senescence and 
increased proliferation likely correlate with a metabolic switch towards aerobic glycolysis. Aerobic 
glycolysis was recently proposed to give an advantage to rapidly proliferating cells, allowing them 
to accumulate NADPH and carbon skeletons needed for anabolic reactions as a side-product of 
glucose consumption and ATP production33. Another important player in oncogenesis is c-myc, 
which contributes to both increased proliferation and aerobic glycolysis, and indeed the levels of c-
myc15, a well known STAT3 target, are elevated in the Stat3C/C MEFs34. 
 Hif-1α is often over-expressed in cancer cells, playing key roles in critical aspects of cancer 
biology, including angiogenesis35, cell survival, genetic instability36, invasion and metastasis37, 
proliferation and metabolism38. Indeed, Hif-1α is a well known inducer of aerobic glycolysis, and it 
was not therefore surprising to find that STAT3-induced glycolysis was Hif-1α-dependent. 
Interestingly, the two-fold transcriptional induction of Hif-1α triggered by constitutively active 
STAT3 was enough to elevate protein levels without inducing protein stabilization, thought to be 
essential for enhanced Hif-1α activity39. Similar to their primary counterparts, immortal Stat3C/C 
cells show Hif-1α-dependent aerobic glycolysis, and Hif-1α silencing reduced, but did not abolish, 
several transformed phenotypes. Thus, STAT3-induced Hif-1α overexpression and aerobic 
glycolysis are important contributors to STAT3-mediated tumorigenesis.  
MEF cells immortalization usually entails loss of function of either the p53 or the ARF 
oncosuppressors40. Interestingly, RAS overexpression induced senescence in Stat3C/C primary 
MEFs, similar to its effect in wild type cells41 (data not shown), possibly because RAS and STAT3 
act in the same signaling cascade. Indeed, STAT3 is phosphorylated on Serine 727 following RAS 
signaling, and it was shown to support RAS-mediated transformation via mitochondrial localization 
and function17. Via induced Ser phosphorylation, RAS might therefore increase STAT3C 
localization to mitochondria, thus reducing its nuclear concentration and activity. We have 
previously shown that nuclear constitutively active STAT3 restrained mitochondrial metabolism in 
both primary MEFs and STAT3-dependent tumor cells by a Hif-1α-independent mechanism16. Also 
3T3 Stat3C/C cells showed decreased mitochondrial activity, which could be rescued by Hif-1α 
silencing. This may reflect the intrinsic heterogeneity in the transformation process, where tumor 
cells may come to rely more heavily on different pathways upon transformation.  
In conclusion, our data suggest that aberrantly constitutively active STAT3 can act as a first 
hit during tumorigenic transformation supporting tumor survival, growth and metabolism, 
strengthening its definition as an oncogene. Thus, drugs inhibiting STAT3 activity might be 
beneficial not only in the therapy of cancer but also in prophylactic treatments aimed at preventing 
the onset of inflammation-driven tumorigenesis. 
 
ACKNOWLEDGMENTS 
We thank A. Camporeale for help with the experiments, M. Wieckowski for helpful discussion and 
for critically reading the manuscript. This work was supported by the Italian Cancer Research 
Association (AIRC), the Italian Ministry for University and Research (FIRB and MIUR), the 
Association for International Cancer Research (AICR), Telethon, the Italian Multiple Sclerosis 
Foundation, the Italian Ministry of Health. 
 
 
 
 
 
 
 
TITLES AND LEGENDS TO FIGURES 
Figure 1. Immortalization and characterization of the Stat3C/C MEFs. A) MEFs were derived 
from E14 embryos of the indicated genotypes and re-seeded at a density of 2*105 cells/10 cm2 every 
3 days as described in the Methods section. Population doubling (PD) was calculated at each 
passage and is shown from passage 10 to 25. B) SOCS3 mRNA levels were measured by Taqman 
RT-PCR in immortalized Stat3C/C (black bars) or WT/WT (white bars) MEFs. C) Immortalized 
Stat3C/C MEFs display increased proliferation rates. 104 cells were plated and cells were counted 
every day for 5 days. 
Figure 2. Transformed features of immortalized Stat3C/C MEFs. A) Phase contrast pictures 
showing multi-layer growth of Stat3C/C MEFs. Magnification 10X. B) Focus forming assay. 30*104 
cells were seeded and the number of colonies scored after 15 days using methyl-violet. WT, 
Stat3WT/WT; C1= Stat3C/C line No I, C2= Stat3C/C line No II. C) Soft-agar growth. 2*104 cells (as in 
B) were seeded in soft agar and colony number evaluated after 30 days. D) STAT3 silencing. 
STAT3 levels were measured by Western Blot in cells of the indicated genotypes, plus or minus 
lentiviral-mediated STAT3 silencing (sh-stat3). ACTIN was used as an internal control, and GFP to 
assess lentiviral infection. E) In vivo tumor growth. 106 cells (Stat3C/C, Stat3WT/WT or Stat3C/C 
silenced for STAT3 - sh-stat3) were inoculated s.c. in the flank in nude mice (n=6), and tumor 
growth was monitored each week for 6 weeks. 
Figure 3. Immortal Stat3C/C MEFs are protected from apoptotic stimuli. A) Stat3C/C (black 
bars) or WT/WT (white bars) MEFs were treated with UV-B (10 J/m2) and stained with Annexin V 
after 24 hours, followed by quantification of positive cells by flow cytometry. B) Same as in A, 
followed by staining for active CASPASE-3 (red). Nuclei were stained in blue by Hoescht. C, D) 
The indicated mRNAs were measured by Taqman RT-PCR in Stat3C/C (black bars) or WT/WT (white 
bars) MEFs. D) Cells as in A were UV-irradiated followed by RNA extraction and RT-PCR 
analysis after 12 hours. *, p ≤ 0,05. 
Figure 4. Aerobic glycolysis in Stat3C/C MEFs. Stat3C/C (black bars) or WT/WT (white bars) MEFs 
were assessed for mRNA levels of the indicated genes by Taqman RT-PCR (A, D) or for their 
accumulation of lactate in the medium 12 hours after seeding (B, C). Lactate production (C) and 
Hif-1α levels (D) were also measured upon Stat3 silencing (sh-stat3). *, p ≤ 0,01 
Figure 5. Hif-1α silencing blunts the oncogenic properties of Stat3C/C MEFs. Stat3C/C MEFs 
either silenced for Hif-1α (striped bars) or infected with a control virus (black bars) were assessed 
for mRNA levels of the indicated genes by Taqman RT-PCR (A) or for their accumulation of 
lactate in the medium 12 hours after seeding (B). C) MEFs of the indicated genotypes were 
transduced with a mitochondria‐targeted aequorin (AEQ), and aequorin activity was measured upon 
challenging with 100 μM ATP. D,E) Stat3C/C MEFs either silenced or not for Hif-1α were tested for 
their ability to form foci and colonies in soft agar (D), or tested for in vivo growth (E) as described 
in the legend to Fig. 1. *, p ≤ 0,01 
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MATERIALS AND METHODS 
Mice, MEFs preparation, cell lines derivation and culture. Stat3C/C mice15 were maintained in 
the transgenic unit of the Molecular Biotechnology Center (University of Turin). Procedures were 
conducted in conformity with national and international laws and policies as approved by the 
Faculty Ethical Committee. Embryos were dissected 13.5 days post coitum for MEF derivation. 
3T3 cell lines were prepared as previously described26.  3T3 MEFs were grown in DMEM with 
GLUTAMAX (Dulbecco’s modified Eagle medium; Gibco-BRL, Carlsbad CA, USA),  
supplemented with 10% (v/v) heat-inactivated FCS (fetal calf serum; Gibco-BRL), 100 U/ml 
penicillin, 100 μg/ml streptomycin. 
Cell proliferation, Focus Forming Assay and soft agar .  
For cell proliferation rate, 1.5*105 cells were seeded in 6-well plates and counted at the indicated 
times using the Countess Automated Cell Culture (Invitrogen, Carlsbad CA, USA). Population 
doublings were calculated using the formula PD = t log 2 / log Nt- log No. 
For the focus forming assay, 30*104 cells were seeded in a 10 cm plate and the media refreshed 
every 2-3 days. After 15 days, cells were fixed in cold methanol and stained with methyl violet 
(Sigma Aldrich, St. Louis MO, USA). Plates were scanned and the number of colonies was 
calculated using the software ImageJ (http://rsbweb.nih.gov/ij/). 
For soft agar assay, 2*104 cells were plated in 0.35% agar in complete growth medium in 3.5 cm 
wells. Colonies were counted 30 days after seeding.  
Lentiviral infection.  
pLKO vectors carrying either scrambled or shRNA-HIF-1α sequences (Open Biosystems, 
Huntsville AL, USA) and pLVTH-GFP carrying either scrambled or shRNA-STAT3 sequences42 
were packaged by transfecting 293T cells and used to infect cells for 24 hours, followed by 
puromycin selection for 48 hours. 
 
 
Sub-cutaneous tumors. 
Female CD-1 mice 5 to 7 weeks of age CD-1 mice (Charles River Laboratories, Inc.) were s.c. 
implanted with 3T3 cells. Cells were harvested using trypsin and washed with PBS. 106 cells were 
resuspended in 200 μL PBS and injected s.c. into the left flank of mice. All mice were monitored 
two times weekly for body weight. S.c. tumors were measured with a caliper weekly, and mice were 
sacrificed whenever the tumor exceeded 10 mm of diameter. 
Real Time-PCR.  
Total RNA was prepared with the PureLink Micro-to-Midi total RNA Purification System 
(Invitrogen). qRT-PCR reactions were performed using the Universal Probe Library system (Roche 
Italia, Monza, Italy). The 18S rRNA pre-developed TaqMan assay (Applied Biosystems) was used 
as an internal control. For primers and probes see Supplementary Information. 
Immunofluorescence.  
Cells plated on glass coverslips were washed in PBS, fixed in 4% paraformaldehyde, quenched with 
50 mmol/L ammonium chloride, permeabilized with 0.3% Triton X-100 in PBS, saturated with 3% 
bovine serum albumin, and incubated with primary antibodies at room temperature for 1 h, followed 
by rhodamine-labeled secondary antibodies (Sigma) and then by Hoechst-dye. An Axiovert 200M 
Zeiss microscope for optical sectioning was used. 
Western blots.  
Total and nuclear protein extracts were obtained as previously described16. Samples were 
fractionated on SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Millipore, 
Billerica MA, USA). 
Lactate measurements 
105 cells were seeded and the media were refreshed 12 hours later. Lactate was measured in cell 
supernatants 3 hours after changing medium using a Lactate Colorimetric Assay Kit (Abcam). Data 
were normalized to final cell counts. 
 
Mitochondrial calcium measurements 
Cells were grown on glass coverslips at 50% confluence and infected with the adenovirus 
expressing the appropriate aequorin chimera as previously described43. Measurements were carried 
out in KRB (125 mM NaCl, 5 mM KCl, 1 mM MgSO4, 1 mM Na2HPO4, 5.5 mM glucose, 20 mM 
NaHCO3, 2 mM l-glutamine and 20 mM HEPES pH 7.4, supplemented with 1 mM CaCl2). ATP 
was added to the same medium. Cells were lysed with 100 μM digitonin in a hypotonic Ca2+-rich 
solution (10 mM CaCl2 in H2O), thus discharging the remaining aequorin pool. The light signal was 
collected and calibrated into [Ca2+] values. 
In vitro cell death. 
Cells were  irradiated with 10 J/m2 UV-C or serum-starved for 48-72 hours, followed by staining 
with either Annexin-V or anti-activated Caspase-3. Annexin-V emission were detected in the green 
channel (525 nm) and propidium iodide in the red channel (575 nm) following excitation by a 488 
nm laser on a FACS Calibur cytometer (Beckton, Dickinson and Company, Franklin Lakes NJ, 
USA). 
Statistical analysis.  
An unpaired t test was used to calculate a P value for two groups, while a P value on a response 
affected by two factors was calculated with a two-way ANOVA. 
 
 
 
 
 
 
 
 
 
  
 
 





